Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

The objectives of this analysis were to evaluate baseline serum levels of proinflammatory biomarkers in participants with TNFi-IR PsA in the COSMOS trial in comparison with healthy controls and the relationship of these biomarker levels with… Statistical analyses This analysis included participants with available baseline values and follow-up biomarker and clinical data over time. While analysis of serum levels allows for collection of serial samples in the clinic, evaluation of tissue would further our knowledge of disease pathogenesis and could potentially help further elucidate the mechanism(s) of action of guselkumab in joints, as preclinical evidence suggests that IL-17 is a key mediator of PsA joint pathogenesis [40]…. Correction Open Access Published:15 September 2023 Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study Georg Schett 1, Warner Chen2, Sheng Gao2, Soumya D. Chakravarty3,4, May Shawi5, Frederic Lavie6, Miriam Zimmermann7, Mohamed Sharaf8, Laura C. Coates9 & …